1009303-42-7

Basic information

• Product Name: (S)-4-(2,7-dichloropyrido[2,3-d]pyriMidin-4-yl)-3-MethylMorpholine
• Synonyms: (S)-4-(2,7-dichloropyrido[2,3-d]pyriMidin-4-yl)-3-MethylMorpholine
• CAS NO: 1009303-42-7
• Molecular Formula: C₁₂H₁₂Cl₂N₄O
• Molecular Weight: 299.15588
• Mol File: 1009303-42-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 429.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.421±0.06 g/cm3(Predicted)
• PKA: 1.69±0.30(Predicted)
• CAS DataBase Reference: (S)-4-(2,7-dichloropyrido[2,3-d]pyriMidin-4-yl)-3-MethylMorpholine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-(2,7-dichloropyrido[2,3-d]pyriMidin-4-yl)-3-MethylMorpholine(1009303-42-7)
• EPA Substance Registry System: (S)-4-(2,7-dichloropyrido[2,3-d]pyriMidin-4-yl)-3-MethylMorpholine(1009303-42-7)

Safety Data

• Hazardous Substances Data: 1009303-42-7(Hazardous Substances Data)

Usage

General Description

(S)-4-(2,7-dichloropyrido[2,3-d]pyriMidin-4-yl)-3-MethylMorpholine is a chemical compound with potential medicinal properties. It contains a pyrido[2,3-d]pyrimidine core, which is commonly found in various pharmaceuticals and bioactive compounds. This particular molecule also contains a morpholine ring and a methyl group, which can affect its pharmacological activity. The presence of the dichloropyrido group on the pyrimidine ring suggests potential interactions with biological targets, making this compound a potential candidate for drug development. Further studies and research are required to fully understand the biological and pharmacological properties of (S)-4-(2,7-dichloropyrido[2,3-d]pyriMidin-4-yl)-3-MethylMorpholine.

Upstream product

• 64321-24-0 2-amino-6-chloro-pyridine-3-carboxamide 

Downstream Products

• 1009303-74-5 (S)-(5-(2-chloro-4-(3-methylmorpholinyl)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol 
• 1009303-54-1 {5-[2-Chloro-4-((R)-3-methyl-morpholin-4-yl)-pyrido[2,3-d]pyrimidin-7-yl]-2-methoxy-phenyl}-methanol 
• 1009303-44-9 (3S)-4-[7-chloro-2-[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d] pyrimidin-4-yl] 3-methyl-morpholine 
• 1009302-61-7 C₂₄H₂₉N₅O₄ 
• 1009302-80-0 C₂₅H₃₂N₆O₃ 
• 1009302-46-8 C₂₄H₃₁N₅O₄ 
• 1009302-47-9 C₂₃H₂₄N₆O₃ 
• 1009298-09-2 AZD₈₀₅₅ 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS MTOR INHIBITORS

The present disclosure describes novel heterocyclic mTOR inhibitors and methods for preparing them. The pharmaceutical compositions comprising such mTOR inhibitors and methods of using them for treating cancer, infectious diseases, and other mTOR associated disorders are also described.

Pyridine and miazines mTOR inhibitors

The invention belongs to the technical field of medicines, and particularly relates to a pyridopyrimidine mammalian target of rapamycin (mTOR) inhibitor which is shown as a general formula (I), pharmaceutically acceptable salts and stereoisomers thereof, and deuterated pyridopyrimidine mammalian mTOR inhibitors, wherein Z, Z, Z, R, R, R, X and W are defined in the specifications. The invention also relates to preparation methods for the compounds, medicinal inhibitors and medicinal compositions which contain the compounds, and the application of the compounds to preparation of medicines for treating and/or preventing post-transplant lymphoproliferative diseases which have response to inhibition of mTOR activity.